About the Company
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TARS News
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript February 27, 2024 Tarsus Pharmaceuticals, Inc.
Tarsus Announces Pricing of $100.0 Million Public Offering
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven ...
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) defied analyst predictions to release its full-year results, which were ahead of market expectations. Revenues of US$17m beat estimates by a substantial ...
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for ...
Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call
David Nakasone; Head of IR; Tarsus Pharmaceuticals, Inc. Bobby Azamian; Chairman & CEO; Tarsus Pharmaceuticals, Inc. Aziz Mottiwala; Chief Commercial Officer; Tarsus ...
Tarsus Announces Pricing of $100.0 Million Public Offering
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on ...
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $35.77, gaining 20.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science ...
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
Good morning, and welcome to Tarsus’s Fourth Quarter and Year-End 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call ...
Tarsus Announces Pricing of $100.0 Million Public Offering
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for ...
Loading the latest forecasts...